Skip to main content
Premium Trial:

Request an Annual Quote

NY State Grants Clinical Lab Permit to Agendia

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Amsterdam-based Agendia said today that New York regulators have granted the firm a clinical laboratory permit, enabling it to receive commercial samples for its MammaPrint breast cancer recurrence assay from NY state residents.

The company said that with the latest permit from the New York State Department of Health, it has all major US clinical laboratory licenses. The firm's MammaPrint test, which is a multivariate index assay, received marketing clearance from the US Food and Drug Administration three years ago.

Agendia also said that the College of American Pathologists has accredited the firm's lab in Huntington Beach, Calif.

"The growing clinical importance of complex genomic testing means that our laboratories need to meet the highest standards of quality for patients and health care professionals," Agendia CEO Bernhard Sixt said in a statement, adding that the permit from New York is "recognized as the most difficult to obtain."

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.